BEACON-AA: Apixabano Com ou Sem Clopidogrel em Doentes com Acidente Vascular Cerebral com Fibrilhação Auricular e Aterosclerose Cerebral
Um Estudo Multicêntrico Prospetivo Randomizado para Avaliar a Eficácia do Apixabano e Clopidogrel na Prevenção do Acidente Vascular Cerebral Isquémico Recorrente em Doentes com Fibrilhação Auricular e Aterosclerose Cerebral
This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30 (±5) days compared with baseline MRI, adjudicated by a central committee.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Although oral anticoagulants are effective in preventing cardioembolic stroke in patients with non-valvular atrial fibrillation (NVAF), a considerable proportion of ischemic strokes in these patients are caused by concomitant large artery atherosclerosis. Carotid or intracranial artery stenosis is present in a substantial number of patients with NVAF and is associated with a higher risk of recurrent cerebral infarction despite standard anticoagulation. In such patients, adding an antiplatelet agent to oral anticoagulation may theoretically reduce atherothrombotic events, but it also raises concern for increased bleeding risk. Recent clinical evidence on this issue remains limited, and the optimal antithrombotic strategy for patients with NVAF and coexisting symptomatic atherosclerotic stenosis has not been clearly established.
The BEACON-AA trial is a multicenter, randomized, open-label, blinded-endpoint (PROBE) study designed to compare the safety and efficacy of apixaban monotherapy versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation (NVAF) and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomized in a 1:1 ratio to receive apixaban alone or apixaban plus clopidogrel for 30 days, followed by apixaban monotherapy thereafter.
Brain MRI including diffusion-weighted and FLAIR sequences will be performed at baseline and at 30 ± 5 days to assess new or recurrent ischemic lesions. The primary efficacy outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee. Secondary efficacy outcomes include: 1) incidence of symptomatic ischemic stroke or transient ischemic attack within 90 days, 2) incidence of acute coronary syndrome within 90 days,3) cardiovascular mortality within 90 days, 4) composite major cardiovascular events within 90 days, 5) all-cause mortality within 90 days, 6) proportion of patients with modified Rankin Scale (mRS) 0-2 at 90 days, and 7) proportion of patients with mRS 0-3 at 90 days. The primary safety outcomes are: 1) incidence of major bleeding within 90 days, defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and 2) incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE)) at 30 ± 5 days after randomization. All imaging and clinical events will be independently adjudicated by blinded central adjudication committees.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Young Dae Kim, M.D. Ph.D.
- Número de telefone: 02-2228-1619
- E-mail: NEURO05@YUHS.AC
Locais de estudo
-
-
-
Busan, Coréia do Sul
- Recrutamento
- Pusan National University Hospital
-
Contato:
- Han-Jin Cho, Professor
- Número de telefone: '+82--51-240-7000
- E-mail: chohj75@gmail.com
-
Busan, Coréia do Sul
- Recrutamento
- Dong-A University Hospital
-
Contato:
- Jung Hwa Seo, Professor
- Número de telefone: +82-51-240-2000
- E-mail: jhseo34@gmail.com
-
Chuncheon, Coréia do Sul
- Recrutamento
- Hallym University Chuncheon Sacred Heart Hospital
-
Contato:
- Chulho Kim, Professor
- Número de telefone: +82-33-240-5000
- E-mail: gumdol52@naver.com
-
Daegu, Coréia do Sul
- Recrutamento
- Keimyung University Dongsan Hospital
-
Contato:
- Sung-Il Sohn, Professor
- Número de telefone: +82-1577-6622
- E-mail: sungil.sohn@gmail.com
-
Goyang, Coréia do Sul
- Recrutamento
- National Health Insurance Service Ilsan Hospital
-
Contato:
- Gyu Sik Kim, Professor
- Número de telefone: '+82-1577-0013
- E-mail: myoungsim@naver.com
-
Incheon, Coréia do Sul
- Recrutamento
- Inha University Hospital
-
Contato:
- Hee-Kwon Park, Professor
- Número de telefone: '+82-32-890-2114
- E-mail: parkhkwon@gmail.com
-
Incheon, Coréia do Sul
- Recrutamento
- Gachon University Gil Medical Center
-
Contato:
- Sang Hee Ha, Professor
- Número de telefone: +82-1577-2299
- E-mail: shha31@naver.com
-
Incheon, Coréia do Sul
- Recrutamento
- Catholic Kwandong University International St. Mary's Hospital
-
Contato:
- Sang-Jun Ahn, Professor
- Número de telefone: +82-1600-8291
- E-mail: neuroan@gmail.com
-
Seoul, Coréia do Sul
- Recrutamento
- Samsung Medical Center
-
Contato:
- Woo-Keun Seo, Professor
- Número de telefone: '+82-2-2-3410-2114
- E-mail: mcastenosis@gmail.com
-
Seoul, Coréia do Sul
- Recrutamento
- Seoul National University Hospital
-
Contato:
- Keun-Hwa Jung, Professor
- Número de telefone: +82-1588-5700
- E-mail: jungkh@gmail.com
-
Seoul, Coréia do Sul
- Recrutamento
- Korea University Anam Hospital
-
Contato:
- Sungwook Yu, Professor
- Número de telefone: '+82-1577-0083
- E-mail: song4yu@korea.ac.kr
-
Seoul, Coréia do Sul
- Recrutamento
- Kangbuk Samsung Hospital
-
Contato:
- Jang-Hyun Baek, Professor
- Número de telefone: '+82-1599-8114
- E-mail: janghyun.baek@gmail.com
-
Seoul, Coréia do Sul
- Recrutamento
- Ewha Womans University Seoul Hospital
-
Contato:
- Tae-Jin Song, Professor
- Número de telefone: +82-1522-7000
- E-mail: knstar@hanmail.net
-
Seoul, Coréia do Sul
- Recrutamento
- Gangnam Severance Hospital
-
Contato:
- Yo Han Jung, Professor
- Número de telefone: +82-1599-6114
- E-mail: YHJUNG@yuhs.ac
-
Seoul, Coréia do Sul
- Recrutamento
- Hanyang University Seoul Hospital
-
Contato:
- Young Seo Kim, Professor
- Número de telefone: +82-2-2290-8114
- E-mail: aescula@hanmail.net
-
Seoul, Coréia do Sul
- Recrutamento
- Kyung Hee University Hospital
-
Contato:
- Jung Hyun Park, Professor
- Número de telefone: +82-2-958-8114
- E-mail: truelove1@hanmail.net
-
Seoul, Coréia do Sul
- Recrutamento
- Kyung Hee University Hospital at Gangdong
-
Contato:
- Il Hyung Lee, Professor
- Número de telefone: +82-1577-5800
- E-mail: neu210@naver.com
-
Seoul, Coréia do Sul
- Recrutamento
- Inje University Sanggye Paik Hospital
-
Contato:
- Sang Won Han, Professor
- Número de telefone: '+82-2-950-1114
- E-mail: sah1puyo@gmail.com
-
Seoul, Coréia do Sul
- Recrutamento
- Kangdong Sacred Heart Hospital
-
Contato:
- Yerim Kim, Professor
- Número de telefone: +821588-4100
- E-mail: brainyrk@gmail.com
-
Seoul, Coréia do Sul
- Recrutamento
- Yonsei University College of Medicine
-
Contato:
- Young Dae Kim, Professor
- Número de telefone: +82-2-2228-1619
- E-mail: NEURO05@YUHS.AC
-
Yŏngin, Coréia do Sul
- Recrutamento
- Yongin Severance Hospital
-
Contato:
- Jinkwon Kim, Professor
- Número de telefone: +82-1899-1004
- E-mail: ANTITHROMBUS@yuhs.ac
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Adults aged 19 years or older at the time of enrollment.
-
Patients with non-valvular atrial fibrillation (NVAF) documented by electrocardiography.
-
Acute ischemic stroke confirmed by brain MRI (diffusion-weighted and FLAIR sequences), with last known well within 120 hours prior to randomization.
-
Presence of clinically significant atherosclerosis in the cerebral or aortic arteries, meeting at least one of the following criteria:
① ≥30% stenosis in the relevant artery (the artery supplying the infarcted territory) demonstrated by CTA, MRA, or DSA - using the WASID criteria for intracranial arteries and NASCET criteria for extracranial arteries.
② High-risk atherosclerotic plaque features in the relevant artery demonstrated by CTA, MRA, or ultrasound, such as ulceration, intraplaque hemorrhage, mobile plaque, or a large lipid core (involving ≥25% of plaque cross-sectional area) on CTA/MRA, or ulceration, mobile plaque, or hypoechoic/echolucent plaque on ultrasound; or presence of branch artery occlusive disease (BAOD).
③ Complex aortic plaque (≥4 mm in thickness, mobile, or ulcerative) identified in the ascending aorta or aortic arch by transthoracic/transesophageal echocardiography or coronary CT angiography.
-
Written informed consent provided by the participant or a legally authorized representative.
Exclusion Criteria:
- Presence of mechanical heart valves or rheumatic mitral stenosis.
- Requirement for antithrombotic agents other than apixaban and clopidogrel.
- Planned percutaneous coronary intervention, coronary artery bypass graft surgery, carotid endarterectomy, or intracranial stenting within 3 months after enrollment.
- Presence of mural thrombus in the heart confirmed by imaging.
- Renal impairment with creatinine clearance ≤25 mL/min.
- Severe hepatic impairment, including acute hepatitis, chronic active hepatitis, hepatic lesions or coagulopathy, hepatic failure, or laboratory evidence of AST/ALT >2× the upper limit of normal (ULN) or total bilirubin ≥1.5× ULN.
- Small-vessel occlusion (lacunar infarction) according to the TOAST classification.
- History within the past 30 days of gastrointestinal bleeding, vascular malformation of the brain or spinal cord, recent brain, spinal, or ophthalmologic surgery or trauma, esophageal varices, or intracranial hemorrhage at any time; or chronic regular use of NSAIDs (≥3 days per week for ≥2 consecutive weeks).
- Ischemic stroke occurring despite concurrent use of both NOAC and antiplatelet therapy.
- Planned surgery or high-bleeding-risk procedure within 3 months, or presence of active bleeding at enrollment.
- Anemia (hemoglobin < 8.0 g/dL) or thrombocytopenia (platelet count < 100,000/µL).
- Pre-stroke modified Rankin Scale (mRS) ≥ 2.
- Severe comorbid illness or malignancy not in complete remission with an expected life expectancy <1 year.
- Known hypersensitivity or allergy to apixaban or clopidogrel.
- Pregnant or breastfeeding women.
- Uncontrolled diabetes mellitus (HbA1c > 10.0%) or severe hypertension (systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg).
- Concomitant use of strong CYP3A4 and P-glycoprotein inhibitors that can significantly increase apixaban exposure (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin).
- Concomitant use of strong CYP2C19 inducers that can enhance clopidogrel antiplatelet effect and increase bleeding risk (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort).
- Clinically significant mass effect due to space-occupying cerebral infarction, or patients expected to require decompressive craniectomy, including those with midline shift > 5 mm, loss of basal cisterns, herniation, fourth-ventricle compression, or obstructive hydrocephalus in posterior fossa infarcts.
- Intracranial hemorrhage or hemorrhagic transformation (PH1 or PH2) according to ECASS criteria.
- Participation in another interventional clinical trial within the past 30 days or concurrent participation in another interventional study (non-interventional observational or registry studies may be allowed at the investigator's discretion).
- Any other condition that, in the investigator's judgment, would make participation or continued involvement in the study inappropriate or infeasible.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Apixaban and Clopidogrel Combination Therapy
Participants receive apixaban(5mg twice daily, or 2.5mg twice daily if indicated) plus clopidogrel 75mg daily for 30days, followed by apixaban monotherapy thereafter. |
Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.
Outros nomes:
Clopidogrel 75mg once daily for 30 days in combination with apixaban, then discontinued.
Outros nomes:
|
|
Comparador Ativo: Apixaban Monotherapy
Participants receive apixaban 5mg(or 2.5mg if indicated) twice daily as monotherapy for 30 days and continue apixaban monotherapy thereafter. |
Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee
Prazo: At 30 ± 5 days after randomization
|
New ischemic lesions, either symptomatic or asymptomatic, identified on DWI/FLAIR at 30 (±5) days compared with baseline MRI, as adjudicated by a central adjudication committee. |
At 30 ± 5 days after randomization
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of symptomatic ischemic stroke or transient ischemic attack (TIA)
Prazo: Within 90 days after randomization
|
Occurrence of new symptomatic ischemic stroke or transient ischemic attack confirmed by clinical and/or imaging criteria. |
Within 90 days after randomization
|
|
Incidence of acute coronary syndrome (ACS)
Prazo: Within 90 days after randomization
|
Occurrence of acute coronary syndrome, including unstable angina or myocardial infarction, confirmed by standard diagnostic criteria. |
Within 90 days after randomization
|
|
Cardiovascular mortality
Prazo: Within 90 days after randomization
|
Death due to fatal stroke, fatal myocardial infarction, or sudden death not clearly attributed to non-vascular causes. |
Within 90 days after randomization
|
|
Composite major cardiovascular events
Prazo: Within 90 days after randomization
|
Composite of recurrent stroke (ischemic or hemorrhagic), acute coronary syndrome, or cardiovascular death. |
Within 90 days after randomization
|
|
All-cause mortality
Prazo: Within 90 days after randomization
|
Death from any cause during the 90-day follow-up period. |
Within 90 days after randomization
|
|
Proportion of patients with modified Rankin Scale (mRS) score 0-2
Prazo: At 90 days after randomization
|
Functional independence defined as mRS score of 0-2 at day 90. |
At 90 days after randomization
|
|
Proportion of patients with modified Rankin Scale (mRS) score 0-3
Prazo: At 90 days after randomization
|
Favorable functional outcome defined as mRS score of 0-3 at day 90. |
At 90 days after randomization
|
|
Incidence of major bleeding events according to the ISTH criteria
Prazo: Within 90 days after randomization
|
Major bleeding events defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria, including fatal bleeding, symptomatic intracranial hemorrhage, intraocular bleeding causing vision loss, bleeding resulting in inability to perform usual activities, bleeding requiring transfusion of ≥2 units of whole blood or red cells, or bleeding leading to hospitalization. |
Within 90 days after randomization
|
|
Incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE))
Prazo: At 30 ± 5 days after randomization
|
Newly developed asymptomatic cerebral hemorrhages identified on MR-Diffusion/FLAIR/SWI(or GRE) performed 30 ± 5 days after randomization. |
At 30 ± 5 days after randomization
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Processos Patológicos
- Doenças cardíacas
- Arritmias Cardíacas
- Doenças Arteriais Oclusivas
- Doenças Arteriais Intracranianas
- Condições Patológicas, Sinais e Sintomas
- Derrame
- Isquemia
- Fibrilação atrial
- Arteriosclerose
- Arteriosclerose Intracraniana
- Compostos de enxofre
- Produtos químicos orgânicos
- Piridinas
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Tiofenos
- Ticlopidina
- Tienopiridinas
- Clopidogrel
- apixaban
Outros números de identificação do estudo
Outros números de identificação do estudo
- 4-2025-0697
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .